Lung cancer patients with COVID-19 in Spain: GRAVID study

Simple item page
dc.contributor.authorProvencio, Mariano
dc.contributor.authorMazarico Gallego, José María
dc.contributor.authorCalles, Antonio
dc.contributor.authorAntoñanzas, Mónica
dc.contributor.authorPangua, Cristina
dc.contributor.authorMielgo Rubio, Xabier
dc.contributor.authorNadal, Ernest
dc.contributor.authorLópez Castro, Rafael
dc.contributor.authorLópez Martín, Ana
dc.contributor.authordel Barco, Edel
dc.contributor.authorDómine, Manuel
dc.contributor.authorFranco, Fernando
dc.contributor.authorDiz, Pilar
dc.contributor.authorSandoval, Carmen
dc.contributor.authorSais Girona, Elia
dc.contributor.authorSullivan, Ivana
dc.contributor.authorSala, Mª Ángeles
dc.contributor.authorGarcía Ledo, Gema
dc.contributor.authorCucurull, Marc
dc.contributor.authorMosquera, Joaquín
dc.contributor.authorMartínez, Mireia
dc.contributor.authorChara, Luis Enrique
dc.contributor.authorArriola, Edurne
dc.contributor.authorEsteban Herrera, Beatriz
dc.contributor.authorJarabo, José Ramón
dc.contributor.authorÁlvarez Álvarez, Rosa
dc.contributor.authorBaena, Javier
dc.contributor.authorGonzález Cao, María
dc.date.accessioned2024-02-05T09:45:55Z
dc.date.available2024-02-05T09:45:55Z
dc.date.created2021-05
dc.date.issued2021-05
dc.description.tableofcontentsfactors are not yet clearly identified. The GRAVID study aimed to describe clinical characteristics, outcomes, and predictors of poor outcome in patients with lung cancer and COVID-19. Methods: Prospective observational study that included medical records of patients with lung cancer and PCR confirmed COVID-19 diagnosis across 65 Spanish hospitals. The primary endpoint was all-cause mortality; secondary endpoints were hospitalization and admission to intensive care units (ICU). Results: A total of 447 patients with a mean age of 67.1 ± 9.8 years were analysed. The majority were men (74.3 %) and current/former smokers (85.7 %). NSCLC was the most frequent type of cancer (84.5 %), mainly as adenocarcinoma (51.0 %), and stage III metastatic or unresectable disease (79.2 %). Nearly 60 % of patients were receiving anticancer treatment, mostly first-line chemotherapy. Overall, 350 (78.3 %) patients were hospitalized for a mean of 13.4 ± 11.4 days, 9 (2.0 %) were admitted to ICU and 146 (32.7 %) died. Advanced disease and the use of corticosteroids to treat COVID-19 during hospitalization were predictors of mortality. Hospitalized, non end-of-life stage patients with lymphocytopenia and high LDH had an increased risk of death. Severity of COVID 19 correlated to higher mortality, ICU admission, and mechanical ventilation rates. Conclusions: Mortality rate was higher among patients treated with corticosteroids during hospitalization, while anticancer therapy was not associated with an increased risk of hospitalization or death. Tailored approaches are warranted to ensure effective cancer management while minimizing the risk of exposure to SARS-CoV-2.es_ES
dc.formatapplication/pdfes_ES
dc.identifier.locationN/Aes_ES
dc.identifier.urihttps://hdl.handle.net/20.500.12080/39500
dc.languageenges_ES
dc.rightsCC-BYes_ES
dc.rights.accessrightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.eses_ES
dc.titleLung cancer patients with COVID-19 in Spain: GRAVID studyes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
PIIS0169500221001938.pdf
Size:
459.57 KB
Format:
Adobe Portable Document Format
Description:
Download

License bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.76 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

1. Artículos
Pontis X logo

in...

Campus de Villanueva de la Cañada. Avd. Universidad, 1 Madrid.

Phone: 91 810 92 00

Email: uaxarchive@uax.es

2025 ©